Science Corporation Raises $400M Series D, Valued at $3.5

Science Corporation Secures $400M Series D at $3.5B Valuation


Science Corporation, the medical technology startup founded in 2021 by former Neuralink president Max Hodak, has raised a $400 million Series D round, the company announced in a blog post. Investors valued the company at $3.5 billion, according to a person familiar with the deal who spoke to TechCrunch. The round included participation from Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.


Hodak, who talked his way into a graduate neuroscience lab as a college student and has pursued biotechnology ever since, co-founded Science to leverage emerging technologies for understanding and interacting with the brain. As of 2026, the company sits at the center of a rapidly maturing neurotech sector, where brain-computer interface (BCI) firms are moving from lab research toward clinical and commercial deployment.


PRIMA: A Vision-Restoring Chip


Science's first product is PRIMA, a wearable and implantable chip designed to help people with age-related macular degeneration recover some vision. The device is approved in Europe and available in Germany, and it is being trialed for additional conditions.


At TechCrunch Disrupt in October 2026, Hodak announced that PRIMA is now being trialed for patients with Stargardt's disease, another blindness-causing condition. Expanding the device's indications reflects a broader 2026 trend in which neurotech developers pursue multiple regulatory pathways simultaneously to accelerate adoption.


Path to the U.S. Market


With the new funding, Science aims to bring PRIMA to the United States through the FDA's Humanitarian Device Exemption (HDE), a regulatory pathway that allows experimental medical technology to be used to treat rare conditions. Science has convinced the FDA that advanced macular degeneration affecting both eyes is uncommon enough to qualify for the exemption, clearing the way to seek approval for U.S. use.


The Long-Term Ambition: A Bio-Hybrid Brain Sensor


Beyond vision restoration, the startup's founding purpose and larger ambition is to connect directly to the human brain through a bio-hybrid sensor built from a combination of cultured neurons and silicon. Science is currently designing initial human trials of the device with Yale neurosurgery professor Murat Günel, who told TechCrunch that the technology could offer potential treatments for Parkinson's disease, among other brain injuries and illnesses.


As of 2026, direct brain-computer interfaces remain largely experimental, but the convergence of cultured-neuron research and silicon engineering represents one of the field's most closely watched frontiers—and Science's new valuation signals strong investor confidence in that long-term vision.

via TechCrunch Startups

Related